Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer

Journal of Molecular Medicine

Volumn 88, Issue 9, 2010, Pages 941-952

  Chen, Guang ^a,b   Yang, Na ^a   Wang, Xiang ^a   Zheng, Si Yuan ^c   Chen, Yi ^a   Tong, Lin Jiang ^a   Li, Yi Xue ^c   Meng, Ling Hua ^a   Ding, Jian ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c Chinese Academy of Sciences   (China)

Author keywords

Biomarker; Cancer; mTOR; p27; Rapalogs; Rapamycin

Indexed keywords

7 HYDROXYSTAUROSPORINE; BIOLOGICAL MARKER; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DASATINIB; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLAVOPIRIDOL; GEFITINIB; LAPATINIB; LETROZOLE; RAPAMYCIN; SMALL INTERFERING RNA; TAMOXIFEN; TEMSIROLIMUS; WORTMANNIN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOPRECIPITATION; MICE; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77956411746     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0635-0     Document Type: Article

References (35)

1. XM Ma J Blenis 2009 Molecular mechanisms of mTOR-mediated translational control Nat Rev Mol Cell Biol 10 307 318 10.1038/nrm2672 10.1038/nrm2672 19339977
2. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 9 22 10.1016/j.ccr.2007.05.008 10.1016/j.ccr.2007.05.008 1:CAS:528:DC%2BD2sXotVyqsr0%3D 17613433
3. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IG Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 10.1056/NEJMoa066838 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D 17538086
4. RJ Motzer B Escudier S Oudard TE Hutson C Porta S Bracarda V Grunwald JA Thompson RA Figlin N Hollaender G Urbanowitz WJ Berg A Kay D Lebwohl A Ravaud 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 10.1016/S0140-6736(08)61039-9 1:CAS:528: DC%2BD1cXps1GmsLY%3D 18653228
5. MS Neshat IK Mellinghoff C Tran B Stiles G Thomas R Petersen P Frost JJ Gibbons H Wu CL Sawyers 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 10.1073/pnas.171076798 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D 11504908
6. Y Shi J Gera L Hu JH Hsu R Bookstein W Li A Lichtenstein 2002 Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 5027 5034 1:CAS:528:DC%2BD38Xmslyksrk%3D 12208757
7. JF Gera IK Mellinghoff Y Shi MB Rettig C Tran JH Hsu CL Sawyers AK Lichtenstein 2004 AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 279 2737 2746 10.1074/jbc.M309999200 10.1074/jbc.M309999200 1:CAS:528:DC%2BD2cXkslyjsw%3D%3D 14576155
8. E Galanis JC Buckner MJ Maurer JI Kreisberg K Ballman J Boni JM Peralba RB Jenkins SR Dakhil RF Morton KA Jaeckle BW Scheithauer J Dancey M Hidalgo DJ Walsh 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 10.1200/JCO.2005.23.622 10.1200/JCO.2005.23.622 1:CAS:528: DC%2BD2MXpslOrtLw%3D 15998902
9. TE Witzig SM Geyer I Ghobrial DJ Inwards R Fonseca P Kurtin SM Ansell R Luyun PJ Flynn RF Morton SR Dakhil H Gross SH Kaufmann 2005 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 5347 5356 10.1200/JCO.2005.13.466 10.1200/JCO.2005.13.466 1:CAS:528:DC%2BD2MXpslOrtLk%3D 15983389
10. GV Thomas C Tran IK Mellinghoff DS Welsbie E Chan B Fueger J Czernin CL Sawyers 2006 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 122 127 10.1038/nm1337 10.1038/nm1337 1:CAS:528:DC%2BD28Xht1Knuw%3D%3D 16341243
11. L Yang MJ Clarke BL Carlson AC Mladek MA Schroeder P Decker W Wu GJ Kitange PT Grogan JM Goble J Uhm E Galanis C Giannini HA Lane CD James JN Sarkaria 2008 PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel Clin Cancer Res 14 3993 4001 10.1158/1078-0432.CCR-07-4152 10.1158/1078-0432.CCR-07-4152 1:CAS:528: DC%2BD1cXntlWru7s%3D 18559622
12. SM Chang P Wen T Cloughesy H Greenberg D Schiff C Conrad K Fink HI Robins L De Angelis J Raizer K Hess K Aldape KR Lamborn J Kuhn J Dancey MD Prados 2005 Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme Invest New Drugs 23 357 361 10.1007/s10637-005-1444-0 10.1007/s10637-005-1444-0 1:CAS:528:DC%2BD2MXmtVymtLY%3D 16012795
13. LH Meng U Shankavaram C Chen K Agama HQ Fu FJ Gonzalez J Weinstein Y Pommier 2006 Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone gamma-H2AX Cancer Res 66 9656 9664 10.1158/0008-5472.CAN-06-0796 10.1158/0008-5472.CAN-06-0796 1:CAS:528:DC%2BD28XhtVams73M 17018623
14. IM Chu L Hengst JM Slingerland 2008 The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy Nat Rev Cancer 8 253 267 10.1038/nrc2347 10.1038/nrc2347 1:CAS:528:DC%2BD1cXjsFCmsLw%3D 18354415
15. C Dong D Wilhelm P Koopman 2004 Sox genes and cancer Cytogenet Genome Res 105 442 447 10.1159/000078217 10.1159/000078217 1:CAS:528:DC%2BD2cXlsV2jsL0%3D 15237232
16. RJ Epstein 2004 The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies Nat Rev Cancer 4 901 909 10.1038/nrc1473 10.1038/nrc1473 1:CAS:528:DC%2BD2cXptFegtrk%3D 15516962
17. PA Oude Weernink M Schmidt KH Jakobs 2004 Regulation and cellular roles of phosphoinositide 5-kinases Eur J Pharmacol 500 87 99 10.1016/j.ejphar.2004. 07.014 10.1016/j.ejphar.2004.07.014 1:CAS:528:DC%2BD2cXotFClurw%3D 15464023
18. Y Luo SO Marx H Kiyokawa A Koff J Massague AR Marks 1996 Rapamycin resistance tied to defective regulation of p27Kip1 Mol Cell Biol 16 6744 6751 1:CAS:528:DyaK28XntVymsL0%3D 8943329
19. A Awada F Cardoso C Fontaine L Dirix J De Greve C Sotiriou J Steinseifer C Wouters C Tanaka U Zoellner P Tang M Piccart 2008 The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics Eur J Cancer 44 84 91 10.1016/j.ejca.2007.10.003 10.1016/j.ejca.2007.10.003 1:CAS:528: DC%2BD2sXhsVOrurjK 18039566
20. S Chan ME Scheulen S Johnston K Mross F Cardoso C Dittrich W Eiermann D Hess R Morant V Semiglazov M Borner M Salzberg V Ostapenko HJ Illiger D Behringer N Bardy-Bouxin J Boni S Kong M Cincotta L Moore 2005 Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer J Clin Oncol 23 5314 5322 10.1200/JCO.2005.66.130 10.1200/JCO.2005.66.130 1:CAS:528: DC%2BD2MXpslOrtLo%3D 15955899
21. J Baselga V Semiglazov P van Dam A Manikhas M Bellet J Mayordomo M Campone E Kubista R Greil G Bianchi J Steinseifer B Molloy E Tokaji H Gardner P Phillips M Stumm HA Lane JM Dixon W Jonat HS Rugo 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 10.1200/JCO.2008.18.8391 10.1200/JCO.2008.18.8391 1:CAS:528: DC%2BD1MXnslWit7s%3D 19380449
22. J Tabernero F Rojo E Calvo H Burris I Judson K Hazell E Martinelli Y Ramon S Cajal S Jones L Vidal N Shand T Macarulla FJ Ramos S Dimitrijevic U Zoellner P Tang M Stumm HA Lane D Lebwohl J Baselga 2008 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 1603 1610 10.1200/JCO.2007.14.5482 10.1200/JCO.2007.14.5482 1:CAS:528:DC%2BD1cXltlWiu7c%3D 18332469
23. F Hong MD Larrea C Doughty DJ Kwiatkowski R Squillace JM Slingerland 2008 mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation Mol Cell 30 701 711 10.1016/j.molcel.2008.04.027 10.1016/j.molcel.2008.04.027 1:CAS:528:DC%2BD1cXnvFWnt78%3D 18570873
24. K Yu L Toral-Barza C Discafani WG Zhang J Skotnicki P Frost JJ Gibbons 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249 258 10.1677/erc.0.0080249 11566616
25. D Agrawal P Hauser F McPherson F Dong A Garcia WJ Pledger 1996 Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3 T3 cells Mol Cell Biol 16 4327 4336 1:CAS:528:DyaK28XksVaksrs%3D 8754833
26. S Hashemolhosseini Y Nagamine SJ Morley S Desrivieres L Mercep S Ferrari 1998 Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability J Biol Chem 273 14424 14429 10.1074/jbc.273.23.14424 1:CAS:528:DyaK1cXjs1Oqsrw%3D 9603954
27. H Tigli N Buyru N Dalay 2005 Molecular analysis of the p27/kip1 gene in breast cancer Mol Diagn 9 17 21 913 10.2165/00066982-200509010-00003 16035731
28. PL Porter KE Malone PJ Heagerty GM Alexander LA Gatti EJ Firpo JR Daling JM Roberts 1997 Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nat Med 3 222 225 10.1038/nm0297-222 1:CAS:528:DyaK2sXpsFSlsA%3D%3D 9018243
29. M Filipits M Rudas H Heinzl R Jakesz E Kubista S Lax W Schippinger O Dietze R Greil W Stiglbauer W Kwasny A Nader M Stierer MF Gnant 2009 Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy Clin Cancer Res 10.1158/1078-0432.CCR-09-0728
30. K Oka Y Suzuki T Nakano 2000 Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognasis Cancer 88 2766 2773 10.1002/1097- 0142(20000615)88:12<2766::AID-CNCR15>3.0.CO;2-G 10.1002/1097- 0142(20000615)88:12<2766::AID-CNCR15>3.0.CO;2-G 1:STN:280: DC%2BD3czivFymug%3D%3D 10870059
31. F Oshita Y Kameda K Nishio G Tanaka K Yamada I Nomura H Nakayama K Noda 2000 Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer Oncol Rep 7 491 495 1:CAS:528:DC%2BD3cXjtVOjur8%3D 10767357
32. JS Carroll DK Lynch A Swarbrick JM Renoir B Sarcevic RJ Daly EA Musgrove RL Sutherland 2003 p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells Cancer Res 63 4322 4326 1:CAS:528:DC%2BD3sXmtFekuro%3D 12907598
33. R Nahta T Takahashi NT Ueno MC Hung FJ Esteva 2004 P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 10.1158/0008-5472.CAN-03-3900 10.1158/0008-5472.CAN-03- 3900 1:CAS:528:DC%2BD2cXksVKns7k%3D 15173011
34. H Xing S Wang K Hu W Tao J Li Q Gao X Yang D Weng Y Lu D Ma 2005 Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy J Cancer Res Clin Oncol 131 511 519 10.1007/s00432-005-0677-9 10.1007/s00432-005-0677-9 1:CAS:528: DC%2BD2MXptVWitr4%3D 15924242
35. U Naumann S Weit L Rieger R Meyermann M Weller 1999 p27 modulates cell cycle progression and chemosensitivity in human malignant glioma Biochem Biophys Res Commun 261 890 896 10.1006/bbrc.1999.1126 10.1006/bbrc.1999.1126 1:CAS:528:DyaK1MXltVagtrs%3D 10441521